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Abstract
The isolation of Mycobacterium tuberculosis from blood culture specimens has been associated with human immunodeﬁciency virus (HIV)
co-infection with variable impact on tuberculosis (TB) mortality reported. The overwhelming majority of M. tuberculosis bacteraemia cases
were described in developing countries. We present a nested case–control analysis of clinical, sociodemographic and behavioural risk
factors in patients with positive M. tuberculosis blood cultures compared with patients with negative blood cultures from a 9-year
population-based active TB surveillance study conducted in Houston, Texas. There were 42 patients with M. tuberculosis bacteraemia, 47
blood culture negative patients and 3573 patients for whom no mycobacterial blood culture was requested. HIV infection was more
common in patients for whom a mycobacterial blood culture was requested (79.8% versus 15.1% p <0.001). Of the patients with
M. tuberculosis bacteraemia, six were HIV negative or had no documentation of HIV status, including ﬁve with immunosuppressive
conditions other than HIV. Patients with M. tuberculosis bacteraemia were more likely than patients with negative blood cultures to be
deceased at diagnosis or to die while on TB therapy (50.0% versus 17.0%, p <0.01), to report men-who-have-sex-with-men behaviour
(31.7% versus 13.0%, p 0.03), to have renal failure (28.6% versus 6.4%, p 0.01), and to have HIV RNA levels higher than 500 000 copies/mL
(61.9% versus 17.2%, p ≤0.01). Requests for mycobacterial culture of blood specimens were more common in HIV-infected individuals, and
the presence of M. tuberculosis bacteraemia was associated with a signiﬁcant increase in mortality.
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The isolation of Mycobacterium tuberculosis from blood samples
of tuberculosis (TB) patients has been documented since the
early twentieth century [1]. However, M. tuberculosis blood
cultures were rarely used as a modality of diagnosing TB until
the human immunodeﬁciency virus (HIV) epidemic occurred,
when mycobacterial blood cultures became widely used to
diagnose disseminated Mycobacterium avium-intracellulare com-
plex disease. It was then noted that M. tuberculosis was
increasingly identiﬁed from blood culture samples. Initially,
the phenomenon was thought to be strictly associated with
co-infection with HIV, but various reports pointed to
M. tuberculosis isolation from blood cultures in HIV-negative
patients as well, albeit at much lower frequency [2,3]. The
usefulness of blood cultures as a diagnostic tool depends on
the pre-test probability of TB in the study population:
Gopinath et al. [3] found that 19 out of 79 (24%) patients
suspected of TB had M. tuberculosis isolated from blood in a
tertiary-care centre in India; while McDonald et al. [4] found
that only 10% of all febrile patients admitted to a hospital in
Malawi or Thailand had mycobacteraemia in 1997. In a more
recent study by Crump et al. [5], 5.7% of febrile patients
admitted to a hospital in Tanzania had M. tuberculosis bacter-
aemia. Mycobacterial blood culture can be a useful diagnostic
adjunct, as documented in a study in HIV-infected individuals in
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Spain where blood was the only source of a positive culture in
15% of 33 patients who were documented as having TB [6].
Predictors of M. tuberculosis bacteraemia include advanced
immunosuppression (as documented by a low CD4 count),
HIV infection, prolonged cough, prolonged fever, weight loss,
lymphadenopathy, left shift in the white blood cell count and
anaemia [2,5–8]. The overall mortality associated with
M. tuberculosis bacteraemia is generally high: 25–55%, probably
a reﬂection of the advanced immunosuppression observed in
these patients [2,5–7]. However, in one prospective study in
Malawi, the presence of M. tuberculosis bacteraemia in HIV/TB
co-infected individuals was not associated with a statistically
signiﬁcant increase in the 1-month mortality: 21% in M. tuber-
culosis bacteraemic versus 32% in not M. tuberculosis-bacterae-
mic patients [9]. In addition, co-infection with HIV does not
seem to predict an additional mortality risk. In a retrospective
medical record review study from Spain, all-cause mortality in
patients with M. tuberculosis bacteraemia was comparable
between the HIV-negative and HIV-positive individuals (25%
and 29%, respectively) [2].
With a few exceptions, the evaluations of the clinical
characteristics of and mortality associated with M. tuberculosis
bacteraemia have been described and performed in developing
countries. We present data on the clinical characteristics and
outcomes of patients with M. tuberculosis bacteraemia, identi-
ﬁed from a 9-year population-based active surveillance study
conducted in Houston, Texas.
Methods
Study population
We conducted a prospective, population-based, active surveil-
lance study of all TB cases reported in Harris County, Texas
(hereafter referred to asHouston) between 1October 1995 and
30 September 2004. Written informed consent was obtained
from all participants. Patients who consented to the study were
interviewed to collect pertinent sociodemographic and behavio-
ural variables. The patients’ next of kin, guardians or proxies
were interviewed when patients were deceased or unable to be
interviewed. Clinical variables were obtained using public health
andmedical record review. All enrolled TB patients were used as
the underlying study population and those who had a mycobac-
terial blood culture requested by the clinician were included in
the nested case–control analysis. The study was approved by the
Institutional Review Boards of the participating institutions.
Mycobacterium tuberculosis isolates
Mycobacterium tuberculosis isolates were collected and molec-
ularly characterized using three genotyping methods: principal
genetic group designation, spoligotyping and restriction frag-
ment length polymorphism (RFLP) of the IS6110 insertion
element [9,10]. Based on the genotypic ﬁndings, isolates were
grouped into ‘clusters’: strains with at least ﬁve IS6110 copies
were considered to be part of the same cluster if they had
matching IS6110 RFLP patterns; strains with fewer than ﬁve
IS6110 copies were considered clustered if they had matching
IS6110 RFLP patterns, spoligotypes and principal genetic group
designations [9,10].
Statistical analysis
Data from study instruments were entered into a MICROSOFT
ACCESS database (Redmond, WA, USA) for storage and
analysis. Characteristics of M. tuberculosis blood-cul-
ture-positive subjects (M. tuberculosis bacteraemic) were com-
pared with those of M. tuberculosis blood culture negative
subjects (not M. tuberculosis bacteraemic) by chi-squared
analysis (or Fisher’s exact testing when at least one cell size
was ≤5); and odds ratios (OR) presented are estimates for the
relative risk associated with M. tuberculosis bacteraemic
patients. Similarly, characteristics of patients with blood
specimens evaluated by culture were compared with patients
without blood specimens evaluated (but statistical measures
are not shown in the tables). Mortality and days to treatment
completion were visualized using Kaplan–Meier methods with
signiﬁcance assessed by Cox Proportional Hazard analysis.
Values of p <0.05 were considered statistically signiﬁcant.
Statistical analyses were conducted with STATA version 10 SE
(StataCorp, College Station, TX, USA) and SAS 9.3 (SAS
Institute Inc., Cary, NC, USA).
Results
During the 9 years of the study, there were 4312 patients with
conﬁrmed TB reported in Houston of whom 3662 (84.9%)
were enrolled and 85.6% of the 3063 culture-positive cases
were enrolled. We identiﬁed 42 patients with TB for whom at
least one M. tuberculosis isolate was recovered from a blood
culture sample and 47 patients with TB for whom a
mycobacterial blood culture sample was requested and was
M. tuberculosis culture negative. Characteristics of patients
with TB with no blood specimen evaluated (n = 3573),
M. tuberculosis bacteraemic patients and the blood culture
negative group are presented in Table 1. Overall, there were
no signiﬁcant differences in the age, race/ethnicity or gender
distribution between theM. tuberculosis bacteraemic and blood
culture negative patients. Patients with M. tuberculosis bacter-
aemia were more likely than blood culture negative patients to
be deceased at diagnosis or to die while on TB therapy (50%
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versus 17.0%, p <0.01), and were more likely to report men
who-have-sex-with-men behaviour (31.7% versus 13.0%,
p 0.03), to have renal failure (28.6% versus 6.4%, p 0.01),
and to have HIV RNA levels (viral load) higher than
500 000 copies/mL (61.9% versus 17.2%, p ≤0.01, Fig. 1).
Human immunodeﬁciency virus co-infection was highly
prevalent (79.8%) among patients for whom a mycobacterial
blood culturewas ordered (85.7% inM. tuberculosis bacteraemic
group and 74.5% in the not M. tuberculosis bacteraemic group),
while HIV co-infection was present in 15.1% of the patients for
whom no mycobacterial blood culture specimen was requested
(p <0.001). Other characteristics that were signiﬁcantly more
common in the group in whom acid-fast bacillus blood culture
specimens was obtained than the group in whom a blood culture
specimen was not obtained were: Black race, birth in the USA,
men who-have-sex-with-men behaviour, fever, disease location
involving both extrapulmonary and pulmonary sites, death at
diagnosis or during therapy, renal failure, cancer diagnosis,
immunosuppressive therapy, aCD4 count less than 200 cells/lL
and an HIV RNA level of >500 000 copies/mL (p <0.05). In
addition, they were more likely to report sweats, chills,
diarrhoea, loss of appetite, dyspnoea and weight loss (data not
shown). However, patients in whom a blood culture specimen
was obtained were less likely to be of Hispanic ethnicity, Asian
race or to complete TB therapy than patients in whom no blood
culture specimen was obtained. (p < 0.05).
Among M. tuberculosis bacteraemic patients, HIV co-infec-
tion was present in 36 (85.7%), two patients were HIV
TABLE 1. Sociodemographic, behavioural and clinical characteristics of patients with tuberculosis not evaluated by blood culture
and in patients with and without Mycobacterium tuberculosis bacteraemia
TB Cases with no blood
specimen evaluated
n = 3573
Mtb blood culture positive
n = 42
Mtb blood culture negative
n = 47 OR p value*
Age median (mean) 42 (41.7) 41 (40.4) 40 (42.0) 0.98 0.43
Male 2402 (67.2%) 34 (81.0%) 32 (68.1%) 1.99 0.16
Race/Ethnicity 0.47
Black 1339 (37.6%) 29 (69.1%) 31 (66.0%) 1.15 0.76
White 555 (15.6%) 4 (9.5%) 6 (12.8%) 0.72 0.74
Hispanic 1207 (33.9%) 8 (19.1%) 5 (10.6%) 1.98 0.37
Asian 458 (12.9%) 1 (2.4%) 4 (8.5%) 0.26 0.37
Foreign born 1333 (37.3%) 7 (16.7%) 9 (19.2%) 0.84 0.76
Current smoker 1470 (41.2%) 15 (36.6%) 27 (57.5%) 0.43 0.05
Near daily alcohol use 1186 (33.3%) 19 (45.2%) 18 (38.3%) 1.33 0.51
Current homelessness 239 (6.7%) 3 (7.1%) 4 (8.5%) 0.83 1.00
Men-who-have-sex-with-men behaviour 241 (6.8%) 13 (31.7%) 6 (13.0%) 3.10 0.03
Injection drug use 306 (8.6%) 5 (12.5%) 8 (17.0%) 0.70 0.76
Fever 2076 (58.6%) 34 (81.0%) 41 (87.2%) 0.62 0.42
Cough 2582 (72.9%) 35 (83.3%) 35 (74.5%) 1.71 0.31
Any drug resistancea 289 (9.7%) 3 (7.1%) 3 (8.3%) 0.85 1.00
Clustered Mtb isolatea 1718 (62.6%) 27 (77.1%) 20 (71.4%) 1.35 0.61
Beijing family isolatea 583 (22.6%) 10 (29.4%) 4 (17.4%) 1.98 0.36
Principal genetic groupa 0.05
Group 1 856 (32.8%) 11 (31.4%) 5 (21.7%) 1.65 0.55
Group 2 1310 (50.2%) 21 (60.0%) 10 (43.5%) 1.95 0.22
Group 3 446 (17.1%) 3 (8.6%) 8 (34.8%) 0.18 0.02
Disease location 0.33
Pulmonary 2602 (72.8%) 15 (35.7%) 20 (42.6%) 0.75 0.51
Extrapulmonary 681 (19.1%) 8 (19.1%) 11 (23.4%) 0.77 0.62
Both 290 (8.1%) 16 (38.1%) 16 (34.0%) 1.19 0.69
Blood only 3 (7.1%) 0 (0%) n/a
Death at diagnosis or during therapy 363 (10.2%) 21 (50.0%) 8 (17%) 4.88 <0.01
Completed TB therapy 2874 (80.4%) 19 (45.2%) 30 (63.8%) 0.32 0.01
Diabetes mellitus 522 (14.6%) 3 (7.1%) 2 (4.3%) 1.73 0.66
Renal failure 135 (3.8%) 12 (28.6%) 3 (6.4%) 5.87 0.01
Cancer 128 (3.6%) 1 (2.4%) 2 (4.3%) 0.94 0.91
Immunosuppressive therapy 30 (0.8%) 3 (7.1%) 2 (4.3%) 7.03 <0.01
HIV diagnosis 541 (15.1%) 36 (85.7%) 35 (74.5%) 2.06 0.18
CD4 <200 cells/μLb 295 (67.5%) 30 (96.8%) 30 (90.9%) 3.00 0.61
HIV RNA >500 000 copies/mLb 58 (21.4%) 13 (61.9%) 5 (17.2%) 7.80 <0.01
HIV, human immunodeﬁciency virus; Mtb, M. tuberculosis; TB, tuberculosis
*p values and OR refer to the comparison between M. tuberculosis blood culture positive and M. tuberculosis blood culture negative patients.
aDenominator limited to subjects with data on M. tuberculosis drug susceptibility or given genotyping method.
bDenominator limited to HIV-infected subjects with CD4 or HIV RNA data within 90 days of diagnosis.
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FIG. 1. Distribution of human immunodeﬁciency virus RNA levels in
Mycobacterium tuberculosis (Mtb) bacteraemic and blood culture
negative patients with tuberculosis (p <0.01).
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seronegative, and four had undocumented HIV serostatus.
Mycobacterium tuberculosis bacteraemic patients with HIV
co-infection had a median CD4 count of 40 cells/lL (mean
56.3). All but one of the six M. tuberculosis bacteraemic
patients with negative/undocumented HIV serology had con-
comitant signiﬁcant immunosuppressive conditions: two
patients had systemic lupus erythematosus with end-stage
renal disease on haemodialysis, one patient with rheumatoid
arthritis receiving methotrexate with a history of cytomega-
lovirus colitis, one patient with diabetes mellitus, agranulocy-
tosis and polymyositis, and one patient on cyclosporine for
renal transplantation. A comparison of the characteristics of
HIV-negative and HIV-positive M. tuberculosis bacteraemic
patients is presented in Table 2.
Clinical presentation
Overall, there were no signiﬁcant differences in the symptoms
on presentation between M. tuberculosis bacteraemic and
blood culture negative patients (Table 1). However, patients
evaluated by blood culture were clearly sicker than those not
evaluated by blood culture, as assessed by symptoms,
co-morbidities, clinical outcomes and, among HIV-co-infected,
CD4 and HIV viral load values (see above).
Mycobacterium tuberculosis isolates
Blood specimens were the only source from which M. tuber-
culosis was isolated in four patients (9.8% of all patients
with M. tuberculosis bacteraemia), including one with
biopsy-conﬁrmed cervical TB lymphadenitis. Drug resistance
was noted in three isolates from three HIV-positive patients
(one isolate was resistant to rifampin, one isolate was resistant
to streptomycin and one isolate was resistant to rifampin and
ethambutol). We genotyped sixM. tuberculosis strains from the
HIV-negative/undocumented M. tuberculosis bacteraemic
patients and 29 M. tuberculosis strains from the HIV-positive,
M. tuberculosis bacteraemic patients: 4 (66.7%) and 23 (79.3%)
of the M. tuberculosis strains belonged to a genotypic cluster,
respectively. The frequency of clustering observed in the
M. tuberculosis bacteraemic patients (77.1%) was comparable to
the frequency of clustering observed in clinical M. tuberculosis
strains in Houston (62.9%) during the same time period (p 0.36)
[11]. Of note, M. tuberculosis bacteraemic patients were less
likely than blood culture negative patients to be infected with a
principal genetic group 3 organism (OR = 0.18, p 0.02) [9].
TB therapy completion
Mycobacterium tuberculosis bacteraemic patients were less likely
than blood culture negative patients to complete TB therapy
(OR = 0.32, p 0.01). Among all TB patients who completed
TB therapy,M. tuberculosis bacteraemic patients took longer to
ﬁnish treatment (n = 19, median 349 days) than blood culture
negative patients (n = 30, median 270 days, p 0.08) and
patients for whom blood cultures specimens were not
evaluated (median 245 days, p <0.01) (Fig. 2a).
Mortality
There were 21 deaths (50%) among the M. tuberculosis
bacteraemic patients and eight deaths (17.0%) among blood
culture negative patients (p <0.01). Fig. 2b shows the Kaplan–
Meier survival curve for patients who were M. tuberculosis
bacteraemic, blood culture negative and for whom blood
specimens were not evaluated. Compared with patients in
whom blood specimens were not evaluated, mortality was
more likely for both M. tuberculosis bacteraemic and blood
culture negative cases: age-adjusted hazard ratios 7.77 (95% CI
4.97–12.13, p <0.01) and 2.10 (95% CI 1.04–4.25, p <0.04),
respectively.
Discussion
We present the clinical characteristics and outcomes from the
largest case series of patients with M. tuberculosis bacteraemia
in an industrialized country. In our series, M. tuberculosis
bacteraemia was predominantly found in HIV-positive patients
and the mortality associated with M. tuberculosis bacteraemia
was signiﬁcantly higher than that seen in TB patients without
documented M. tuberculosis bacteraemia. In 9.8% of the cases
TABLE 2. Sociodemographic and clinical characteristics of
patients with Mycobacterium tuberculosis bacteraemia by HIV
status
HIV-positive
n = 36
HIV-negative/undocumented
n = 6
Male 31 (86.1%) 3 (50%)
Race
Black 26 (72.2%) 3 (50%)
White 4 (11.1%) 0
Hispanic 6 (16.7%) 2 (33.3%)
Asian 0 1 (16.7%)
Foreign born 6 (16.7%) 1 (16.7%)
Age median (mean) 40.5 (40.0) 44.0 (42.7)
Smoker 15 (42.9%) 0
Near daily alcohol use 19 (52.8%) 0
Disease sitea
Pulmonary 12 (33.3%) 3 (50%)
Extrapulmonary 8 (22.2%) 0
Both 13 (36.1%) 3 (50%)
Only blood 3 (8.3%) 0
Cavities on chest X-ray 4 (11.1%) 3 (50%)
Any drug resistanceb 3 (8.3%) 0
Beijing spoligotypeb 7 (25%) 3 (50%)
Positive TB skin testc 6 (27.3%) 2 (40%)
HIV, human immunodeﬁciency virus; TB, tuberculosis
aIn addition to isolation of M. tuberculosis from blood cultures, the patients had
clinical evidence of TB involving the lungs (pulmonary), organs other than the lungs
(extrapulmonary) or both.
bDenominator limited to subjects with data on M. tuberculosis drug susceptibility
or spoligotyping.
cWe found documentation of TB skin test results for ﬁve HIV-negative/
undocumented and 22 HIV-positive patients.
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of M. tuberculosis bacteraemia, blood was the only positive
source for M. tuberculosis isolation.
Our case series and other case series have documented the
association between HIV and M. tuberculosis bacteraemia.
Importantly, we found that other relatively common immuno-
suppressing conditions may be associated with isolation of
M. tuberculosis from the blood. In fact, we may be underesti-
mating the importance of M. tuberculosis bacteraemia in
HIV-negative patients because clinicians were more likely to
order mycobacterial blood culture in HIV-infected patients: HIV
infection was present in 79.8% of patients for whom a
mycobacterial blood culture was obtained, whereas HIV
infection was present in only 15.1% of the TB patients in
Houston for whom no mycobacterial blood cultures were
obtained. Also, patientswithmore overt symptoms (fever, chills,
sweats, weight loss) were more likely to have acid-fast bacilli
blood culture specimens obtained; which also denotes that we
may be underestimating the prevalence of M. tuberculosis
bacteraemia in TB patients with fewer overt symptoms. Given
that the number of patients on immunosuppressive medications
or of individuals living with immunosuppressing conditions is
growing, mycobacterial blood cultures should be considered in
such patients with unexplained fever as an adjunctive diagnostic
modality, especially in the presence of other TB risk factors
(immigration, minority status, exposure history). Notably, we
found that for patients who completed therapy, the time from
therapy initiation to completion was longer than the typical
180 days of therapy expected for most patients. We did not
examine the records speciﬁcally for factors contributing to the
longer time to therapy completion, but potential factors
contributing include treatment interruptions due to drug
reactions, episodes of loss to follow up (most of our patients
received directly observed therapy) and hospital admission(s).
Identifying these factors is important, as it may result in changes
that would improve the cost efﬁciency of TB treatment.
In our study, the mortality of patients with M. tuberculosis
bacteraemia was signiﬁcantly higher than that found in both
blood culture negative cases and TB patients not evaluated by
blood culture. Mortality was not always assessed in previous
studies, and when evaluated, mortality was not always found to
be increased in patients with M. tuberculosis bacteraemia [2,6–
8]. Most other studies have not evaluated mortality system-
atically through therapy completion; and this could be the
reason for the difference, although one can see that the
survival curves start diverging early in our TB population
(Fig. 2b). Increased mortality in M. tuberculosis bacteraemic
patients can be partially explained by the advanced immuno-
suppression in this group of patients: all but one of the
HIV-positive patients had CD4 counts below 200 cells/lL, and
all but one HIV-negative/undocumented had signiﬁcant immu-
nosuppressing co-morbidities. Recently, Abdool Karim et al.
[12] demonstrated that initiation of antiretrovirals within
2 months of initiating TB therapy improved survival, when
compared with delayed initiation of therapy. This points to
reversal of immunosuppression (at least partially) as an
important factor in improving the outcomes of patients with
M. tuberculosis bacteraemia. In our study, HIV-infected patients
who were M. tuberculosis bacteraemic had signiﬁcantly higher
HIV viral loads than blood culture negative patients (Fig. 1).
Other investigators have documented that an elevated HIV
RNA level is an independent predictor of the incidence of
opportunistic infections, including extrapulmonary TB [13,14].
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FIG. 2. Kaplan–Meier curves for Mycobacterium tuberculosis (Mtb)
bacteraemic, blood culture negative and tuberculosis (TB) cases for
whom blood specimens were not evaluated: (a) Estimates of days to
TB therapy completion for patients that completed treatment (p 0.08
and p <0.01 comparing blood culture negative and not-evaluated
groups to the Mtb bacteraemic group, respectively). (b) Probability of
survival, where death occurred either at TB diagnosis or while on
therapy (age-adjusted p <0.01 and p 0.04 comparing Mtb bacteraemic
and blood culture negative groups to the not-evaluated group,
respectively).
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Our study has its limitations, the most evident of which is
that mycobacterial blood cultures were not systematically
collected on all patients. This probably resulted in an
underestimation of the frequency of M. tuberculosis bactera-
emia, which was 1.1% in our study population. Depending on
the epidemiological setting and the criteria used to obtain the
blood cultures, other studies have shown the prevalence of
M. tuberculosis bacteraemia of 5 to >30% [4,15,16]. Another
limitation is the possibility that mycobacterial blood culture
results might have been missed in the abstraction of medical
records, especially if the result was negative. However, such
omissions are not expected to affect the observed increased
mortality in patients with M. tuberculosis bacteraemia.
In summary, mycobacterial blood cultures are potentially
useful diagnostic adjuncts. M. tuberculosis bacteraemia identi-
ﬁed in a large metropolis in the USA is associated with
advanced immunosuppression (HIV or non-HIV-related immu-
nosuppression) and with signiﬁcantly increased mortality.
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